- Topic1/3
46k Popularity
4k Popularity
3k Popularity
364 Popularity
486 Popularity
- Pin
- 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
1️⃣ #ETH Hits 4800# | Market Analysis & Prediction: Boldly share your ETH predictions to showcase your insights! 10 lucky users will split a 0.1 ETH prize!
Details 👉 https://www.gate.com/post/status/12322612
2️⃣ #Creator Campaign Phase 2# |ZKWASM Topic: Share original content about ZKWASM or its trading activity on X or Gate Square to win a share of 4,000 ZKWASM!
Details 👉 https://www.gate.com/post/st - 📢 Gate Square #Creator Campaign Phase 2# is officially live!
Join the ZKWASM event series, share your insights, and win a share of 4,000 $ZKWASM!
As a pioneer in zk-based public chains, ZKWASM is now being prominently promoted on the Gate platform!
Three major campaigns are launching simultaneously: Launchpool subscription, CandyDrop airdrop, and Alpha exclusive trading — don’t miss out!
🎨 Campaign 1: Post on Gate Square and win content rewards
📅 Time: July 25, 22:00 – July 29, 22:00 (UTC+8)
📌 How to participate:
Post original content (at least 100 words) on Gate Square related to
Ethena's revenue skyrocketed to 290 million USD, seeking clarity from the SEC on USDe.
Ethena Labs achieved accrued revenue of 290.2 million USD from the protocol on July 9, ranking just behind Tether, Circle, and Sky among stablecoin issuers. This issuer reached 100 million USD in accumulated revenue just 251 days post-launch, becoming the second-fastest protocol to surpass this threshold. The average daily fee reached 3.1 million USD as traders continued to use the USDe token. Ethena generates core revenue from holding futures positions across multiple exchanges. 94% of collateral assets remain on centralized platforms, and 20% of gross fees are used to purchase ENA on the open market. Ethena has met with the SEC to clarify about the “aggregate dollar” USDe, but remains prohibited from retail distribution in America while awaiting official guidance.